• Crisaborole

    Crisaborole

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Crisaborole Atopic Dermatitis And Eczema  Pfizer  
  • Etelcacetide

    Etelcacetide

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Etelcacetide Secondary hyperparathyroidism(HPT) Amgen  
  • Abemaciclib

    Abemaciclib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Abemaciclib Breast cancer, prostate cancer treatment Eli Lily  Dec.15,2029
  • Deucracitinib

    Deucracitinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Deucracitinib Anti plaque psoriasis Bristol-Myers Squibb Company  Nov.07,2033
  • Apremilast

    Apremilast

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Apremilast psoriatic arthritis Celgene  
  • Remdesivir

    Remdesivir

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Remdesivir Antiviruls(Ebola, Covid-19) Gilead  

     

  • Paxlovid

    Paxlovid

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Paxlovid Covid-19  Pfizer  

     

  • Pomalidomide

    Pomalidomide

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Pomalidomide Oncology drug  Celgene   

     

  • Nirmatrelvir

    Nirmatrelvir

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Nirmatrelvir 3C-Like Protease (3CLPRO) Inhibitor And SARS-Cov-2 Mpro Inhibitor    

     

  • Eltrombopag

    Eltrombopag

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Eltrombopag ITP & Aplastic anemia  Novartis & GSK  May. 20, 2023
  • Ruxolitinib

    Ruxolitinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Ruxolitinib Myelofibrosis Novartis Jul. 6, 2024
  • Crisaborole

    Crisaborole

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Crisaborole Atopic Dermatitis and Eczema Pfizer Jun. 11, 2026